Expanding a prospective, clinical trial examining the immune response of participants receiving Modified Vaccinia Ankara vaccine to Africa
Who are we?
The Mpox epidemic in Democratic Republic of Congo (DRC) is accelerating at an alarming rate, and a significant number of cases have been reported beyond DRC's borders. The surge has led the World Health Organisation (WHO) to issue its highest global health alert - a Public Health Emergency of International Concern (PHEIC). According to the latest available data, the cumulative number of cases in DRC for 2024 is over 20,000, including over 600 deaths, with cases reported in 13 countries across the African continent.
The scope of the Mpox AFRIVAC Project includes sharing of new technology in Mpox diagnostics with affected countries, determining the relative immunogenicity of Mpox vaccination in immunosuppressed individuals and women as well as comparing the durability of immune responses in different populations (European versus African). By significantly leveraging the clinical and laboratory structure developed by the pre-existing MpoxVax trial, this new knowledge, generated by experienced researchers in populations most affected, is realistic to complete within the indicated budget and available timelines. Additionally, this Project will contribute to wider research to determine a correlate of protection that can be used clinically to determine vaccine effectiveness in terms of thresholds of immunity as well as appropriate interval re-vaccination strategies. The partners link expertise in vaccine clinical trials, virology, diagnostics development, biobanking and global health, focused on countries and populations most affected by Mpox, that are capable of successfully realising the Mpox AFRIVAC Project’s ambition.
Objective 1
Either describe the objective, or highlight something important of the Mpox Vax project
Objective 2
Either describe the objective, or highlight something important of the Mpox Vax project
Objective 3
Either describe the objective, or highlight something important of the Mpox Vax project
Who is involved in this project?
A brief description of the countries involved in the project (without describing the people, that will be in more detail in about us)
UCD
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND
MLI
MAKERERE UNIVERSITY LUNG INSTITUTE, UGANDA
UNHRO
UGANDA NATIONAL HEALTH RESEARCH ORGANISATION
USTAN
UCB
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS, UK
UNIVERSITE CATHOLIQUE DE BUKAVU, DRC
NMIR
NATIONAL INSTITUTE FOR MEDICAL RESEARCH, TANZANIA
Work Packages of the project
A brief description of the Work Packages of this project, maybe touching in some of the importan
Work Package 01.
Project Management and Consortium Coordination
WP1 comprises all managerial and coordination activities that ensure MpoxVax AFRIVAC meets its defined objectives and overall ambition.
Work Package 02.
Scientific Project Leadership and Clinical Trial
WP2 will adapt and conduct the MpoxVax clinical trial for the evaluation of humoral immune responses of participants at risk of Mpox infection receiving the Modified Vaccinia Ankara (MVA) vaccine in Uganda, Tanzania and the Democratic Republic of Congo.
Work Package 03.
Laboratory assays and biobanking
Set up the laboratory assay harmonisation programme including quality control/ quality assurance among the participating laboratories and to adapt and validate the novel serological immunoassay
Work Package 04.
Training and Dissemination
WP04 will be responsible for Community Engagement, Knowledge Exchange and technology transfer for the project.
Would you like to be updated on this project?
Sign up to our Newsletter
Text just describing what will the newsletter contain,
Our locations
Address of all the hospitals involved.
Contact
Phone: +1 123-456-7890
Email: mail@example.com